MENU

XTLB Stock XTL Biopharmaceuticals (XTLB, $1.2) Stochastic Oscillator left the oversold zone on September 17, 2025

A.I.dvisor
at Tickeron.com
Loading...
XTLB - XTL Biopharmaceuticals Ltd
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $1.2
Daily change: -$0.02 (-1.64%)
Daily volume: 4.3K
Industry: Biotechnology
This is a signal that XTLB's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 72 similar cases where XTLB's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

XTLB's Stochastic Oscillator is remaining in oversold zone for 6 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where XTLB advanced for three days, in of 182 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XTLB as a result. In of 126 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XTLB turned negative on September 19, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 60 similar instances when the indicator turned negative. In of the 60 cases the stock turned lower in the days that followed. This puts the odds of success at .

XTLB moved below its 50-day moving average on September 10, 2025 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for XTLB moved below the 200-day moving average on September 22, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XTLB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XTLB broke above its upper Bollinger Band on September 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XTLB entered a downward trend on September 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.930) is normal, around the industry mean (19.714). P/E Ratio (0.000) is within average values for comparable stocks, (54.201). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.145). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (18.587) is also within normal values, averaging (346.197).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XTLB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XTLB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
XTLB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

a developer of therapeutics to treat hepatitis and other infectious diseases, using human antibodies and synthetic chemicals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
5 Badner Street
Phone
+972 36116600
Employees
4
Web
https://www.xtlbio.com